Leyla Arik

771 total citations
17 papers, 463 citations indexed

About

Leyla Arik is a scholar working on Molecular Biology, Organic Chemistry and Genetics. According to data from OpenAlex, Leyla Arik has authored 17 papers receiving a total of 463 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Organic Chemistry and 7 papers in Genetics. Recurrent topics in Leyla Arik's work include Coagulation, Bradykinin, Polyphosphates, and Angioedema (7 papers), Adenosine and Purinergic Signaling (6 papers) and Synthesis and Biological Evaluation (6 papers). Leyla Arik is often cited by papers focused on Coagulation, Bradykinin, Polyphosphates, and Angioedema (7 papers), Adenosine and Purinergic Signaling (6 papers) and Synthesis and Biological Evaluation (6 papers). Leyla Arik collaborates with scholars based in United States, Italy and Germany. Leyla Arik's co-authors include Carolyn Foster, Deen Tulshian, Bernard R. Neustadt, Jean E. Lachowicz, Jinsong Hao, Andrew W. Stamford, William J. Greenlee, G R Johnson, Kwokei Ng and Ho-Sam Ahn and has published in prestigious journals such as Journal of Biological Chemistry, Biochemical Journal and Journal of Medicinal Chemistry.

In The Last Decade

Leyla Arik

17 papers receiving 432 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Leyla Arik United States 13 212 184 162 70 59 17 463
J. Paul Hieble United States 10 133 0.6× 104 0.6× 13 0.1× 18 0.3× 18 0.3× 15 403
Nicholas D. Kindon United Kingdom 15 285 1.3× 262 1.4× 241 1.5× 60 0.9× 6 0.1× 27 764
Anna Melone Switzerland 11 337 1.6× 165 0.9× 14 0.1× 19 0.3× 57 1.0× 18 523
Malbinder Fagura United Kingdom 9 127 0.6× 75 0.4× 174 1.1× 38 0.5× 4 0.1× 9 346
Robert E. West United States 15 371 1.8× 137 0.7× 65 0.4× 5 0.1× 37 0.6× 27 748
Denise Rageot Switzerland 13 373 1.8× 269 1.5× 11 0.1× 19 0.3× 57 1.0× 19 640
Joseph L. Balwierczak Switzerland 13 178 0.8× 22 0.1× 52 0.3× 13 0.2× 53 0.9× 23 343
Isabella Pugliesi Italy 12 208 1.0× 138 0.8× 76 0.5× 8 0.1× 9 0.2× 16 461
Barry Teobald United Kingdom 6 136 0.6× 287 1.6× 109 0.7× 53 0.8× 4 0.1× 6 535
Kalpana Patel United States 12 208 1.0× 10 0.1× 47 0.3× 19 0.3× 21 0.4× 28 481

Countries citing papers authored by Leyla Arik

Since Specialization
Citations

This map shows the geographic impact of Leyla Arik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leyla Arik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leyla Arik more than expected).

Fields of papers citing papers by Leyla Arik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leyla Arik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leyla Arik. The network helps show where Leyla Arik may publish in the future.

Co-authorship network of co-authors of Leyla Arik

This figure shows the co-authorship network connecting the top 25 collaborators of Leyla Arik. A scholar is included among the top collaborators of Leyla Arik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leyla Arik. Leyla Arik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Qian, Wenyuan, Jian Jeffrey Chen, Jiawang Zhu, et al.. (2011). Discovery of dehydro-oxopiperazine acetamides as novel bradykinin B1 receptor antagonists with enhanced in vitro potency. Bioorganic & Medicinal Chemistry Letters. 22(2). 1061–1067. 7 indexed citations
2.
Bryan, Marian C., Kaustav Biswas, Robert M. Rzasa, et al.. (2011). Chromenones as potent bradykinin B1 antagonists. Bioorganic & Medicinal Chemistry Letters. 22(1). 619–622. 9 indexed citations
3.
Biswas, Kaustav, Marian C. Bryan, Leyla Arik, et al.. (2011). Discovery of Potent, Orally Bioavailable Phthalazinone Bradykinin B1 Receptor Antagonists. Journal of Medicinal Chemistry. 54(20). 7232–7246. 25 indexed citations
4.
Liu, Qingyian, Wenyuan Qian, Kaustav Biswas, et al.. (2010). Aryl sulfonamides containing tetralin allylic amines as potent and selective bradykinin B1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 20(15). 4593–4597. 4 indexed citations
5.
Biswas, Kaustav, Wenyuan Qian, Jian Jeffrey Chen, et al.. (2008). Aryl sulfones as novel Bradykinin B1 receptor antagonists for treatment of chronic pain. Bioorganic & Medicinal Chemistry Letters. 18(17). 4764–4769. 16 indexed citations
6.
Neustadt, Bernard R., Hong Liu, Jinsong Hao, et al.. (2008). Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines. Bioorganic & Medicinal Chemistry Letters. 19(3). 967–971. 34 indexed citations
7.
Chen, Jian Jeffrey, Wenyuan Qian, Kaustav Biswas, et al.. (2008). Discovery of dihydroquinoxalinone acetamides containing bicyclic amines as potent Bradykinin B1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 18(16). 4477–4481. 35 indexed citations
8.
Chackalamannil, Samuel, Bernard R. Neustadt, William J. Greenlee, et al.. (2008). Biaryl and heteroaryl derivatives of SCH 58261 as potent and selective adenosine A2A receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 18(14). 4199–4203. 17 indexed citations
9.
Caldwell, John P., William J. Greenlee, Julius J. Matasi, et al.. (2007). 3H-[1,2,4]-Triazolo[5,1-i]purin-5-amine derivatives as adenosine A2A antagonists. Bioorganic & Medicinal Chemistry Letters. 17(6). 1659–1662. 14 indexed citations
10.
Neustadt, Bernard R., Jinsong Hao, William J. Greenlee, et al.. (2006). Potent, selective, and orally active adenosine A2A receptor antagonists: Arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines. Bioorganic & Medicinal Chemistry Letters. 17(5). 1376–1380. 112 indexed citations
11.
Tulshian, Deen, et al.. (2005). 6-(2-Furanyl)-9H-purin-2-amine derivatives as A2A adenosine antagonists. Bioorganic & Medicinal Chemistry Letters. 15(8). 2119–2122. 23 indexed citations
12.
Matasi, Julius J., John P. Caldwell, Jinsong Hao, et al.. (2005). The discovery and synthesis of novel adenosine receptor (A2A) antagonists. Bioorganic & Medicinal Chemistry Letters. 15(5). 1333–1336. 39 indexed citations
13.
Ahn, Ho-Sam, Leyla Arik, George Boykow, et al.. (1999). Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 9(14). 2073–2078. 38 indexed citations
14.
Ahn, Ho-Sam, Carolyn Foster, George Boykow, et al.. (1997). Binding of a Thrombin Receptor Tethered Ligand Analogue to Human Platelet Thrombin Receptor. Molecular Pharmacology. 51(2). 350–356. 46 indexed citations
15.
Ahn, Ho-Sam, Michael A. Foster, Leyla Arik, George Boykow, & Carolyn Foster. (1995). Cyclic nucleotide phosphodiesterase isozymes in rat mesangial cells. European Journal of Pharmacology Molecular Pharmacology. 289(1). 49–57. 4 indexed citations
16.
Johnson, G R, Leyla Arik, Barry J.R. Pitts, & Carolyn Foster. (1990). Rapid receptor-mediated catabolism of 125I-atrial natriuretic factor by vascular endothelial cells. Biochemical Journal. 268(3). 771–776. 13 indexed citations
17.
Johnson, G R, Leyla Arik, & Carolyn Foster. (1989). Metabolism of 125I-atrial natriuretic factor by vascular smooth muscle cells. Journal of Biological Chemistry. 264(20). 11637–11642. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. Paul Hieble Breakdown of academic impact, for papers by Nicholas D. Kindon Breakdown of academic impact, for papers by Anna Melone Breakdown of academic impact, for papers by Malbinder Fagura Breakdown of academic impact, for papers by Robert E. West Breakdown of academic impact, for papers by Denise Rageot Breakdown of academic impact, for papers by Joseph L. Balwierczak Breakdown of academic impact, for papers by Isabella Pugliesi Breakdown of academic impact, for papers by Barry Teobald Breakdown of academic impact, for papers by Kalpana Patel
Rankless by CCL
2026